

EuroBio 09
Lille
September 24, 2009


The IMIDIA Consortium

Bernard Thorens

University of Lausanne

Unil

UNIL | Université de Lausanne



IMIDIA

IMI Call topic: Islet Cell Research

IMIDIA: Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes

IMIDIA

Letter of Intent:

submitted in July 2008

12 academic institutions

1 SME

LOI selected for 2nd phase selection in September 2008

IMIDIA

- **Preparation of full proposal with academic partners, SME and 9 Pharma partners**
- **Full proposal submitted in January 2009**
- **Project accepted in March 2009**

IMIDIA

Goals of IMIDIA:

- 1- Novel tools for the study of human beta-cell development, function and survival; their modulation by potential therapeutic compounds; and for in vivo beta-cell imaging.
- 2- Biomarkers for the diagnosis and prognosis of beta-cell failure and for monitoring diabetes progression and treatment.
- 3- Knowledge on novel pathways and sites that control beta-cell proliferation, differentiation and apoptosis, and on the role of known nutrient regulated pathways and sites in controlling beta-cell mass and function.

IMIDIA

Current status:

- **Negotiation of the Project Agreement**
- **Deadline for signature of all documents: November 30, 2009**
- **Expected start of the project: end of 2009**

IMIDIA

Budget:

EU funding to academic and SME partners: 7.0 Mio €

Estimated pharma in kind contribution: 15.0 Mio €

**Note: EU funding to academic and SME partners is
75% of actual costs plus 20% overhead.
=> Need for outside resources.**

IMIDIA

Expectations from public-private partnership:

- **Real intellectual contribution from Pharmas to the research plan.**
- **Real and effective in kind contribution by Pharmas to ensure maximum chances or reaching research goals.**
- **Fair and reasonable terms to share research results for direct exploitation.**
- **Open negotiation of the terms of the Project Agreement and Grant Agreement, as opposed to IMI-JU (Pharma) imposed, non-negotiable terms.**